Aurobindo Pharma Ltd Share Price
(AUROPHARMA)
₹1165.8▲2.86%
as on 02:15PM, 17 Apr 2025
Aurobindo Pharma Performance
Day's Low
Day's High
₹1,131.4Day's Price Range₹1,165.952 Week's Low
52 Week's High
₹1,01052-Week Price Range₹1,592
| Returns % | |
| 1 Month Return | + 1.95 % |
| 3 Month Return | -3.81 % |
| 1 Year Return | + 1.7 % |
| Market Stats | |
| Previous Close | ₹1,133.40 |
| Open | ₹1,165.40 |
| Volume | 4.54L |
| Upper Circuit | ₹1,246.70 |
| Lower Circuit | ₹1,020.10 |
| Market Cap | ₹66,410.28Cr |
Aurobindo Pharma Fundamentals
P/E Ratio
18.97
PEG Ratio
1.52
Market Cap
₹66,410.28 Cr
P/B Ratio
3.24
EPS
54.09
Dividend Yield
0.41
Sector
Pharmaceuticals
ROE
10.35
Mutual Fund Holdings of Aurobindo Pharma
Aurobindo Pharma Analyst Rating
based on 28 analysts
78.57%
Buy
7.14%
Hold
14.29%
Sell
Based on 28 analysts offering long term price targets for Aurobindo Pharma. An average target of ₹1477.43
Source: S&P Global Market Intelligence
Aurobindo Pharma Share analysis
Aurobindo Pharma price forecast by 28 analysts
Upside of30.35%
High
₹1930
Target
₹1477.43
Low
₹1140
Aurobindo Pharma target price ₹1477.43, a slight upside of 30.35% compared to current price of ₹1165.8. According to 28 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Aurobindo Pharma revenue growth forecast
Expected growth rate Q1, FY2027:28.23%
Forecast
Actual
Including amortisation and stock based compensations
Aurobindo Pharma EPS growth forecast
EPS estimate Q1, FY2027:51.07%
Forecast
Actual
Source: S&P Global Market Intelligence
Key events for Aurobindo Pharma Ltd
Aurobindo Pharma Gains USFDA Approval for Rivaroxaban - 12 Apr, 2025
Aurobindo Pharma has received USFDA approval for Rivaroxaban Tablets USP, 2.5 mg, with a market potential of $447 million. Tentative approvals for higher strengths could lead to a total market size of $8.5 billion, enhancing Aurobindo's position in the US market.Aurobindo Pharma Faces FDA Scrutiny Amid Trial Success - 11 Apr, 2025
Aurobindo Pharma shares surged 5% following positive Phase 1 trial results for BP16, while the company also faced FDA scrutiny at its North Carolina plant, receiving a Form 483 with 11 observations. The company is committed to addressing these observations without expecting material impact on operations.Aurobindo Pharma Completes Phase 1 Trials for BP16 - 10 Apr, 2025
Aurobindo Pharma's subsidiary, CuraTeQ Biologics, successfully completed Phase 1 trials for BP16, a new bone treatment. However, the stock has declined 9% weekly and 22-23% year-to-date.Aurobindo Pharma Faces Tariff Threats Amid Drug Success - 09 Apr, 2025
On April 9, Aurobindo Pharma faced a stock decline due to Trump's tariff threats while also reporting successful Phase 1 trial results for osteoporosis drug BP16.Aurobindo Pharma Gains EU Approval Amid Profit Decline - 07 Apr, 2025
Aurobindo Pharma's subsidiary, CuraTeQ Biologics, received EU approval for Dyrupeg, a biosimilar. However, the company reported a 10.04% decline in Q3 FY25 net profit.Aurobindo Pharma Secures EU Approval for Dyrupeg - 05 Apr, 2025
Aurobindo Pharma's subsidiary, CuraTeQ Biologics, received EU marketing authorization for Dyrupeg™, a pegylated filgrastim biosimilar. This approval enhances Aurobindo's biosimilar portfolio in Europe, providing a cost-effective treatment option for patients with low white blood cell counts.Aurobindo Pharma Shares Plummet Amid Tariff Concerns - 04 Apr, 2025
On April 4, 2025, Aurobindo Pharma's shares dropped significantly, falling up to 10% due to U.S. President Trump's remarks about impending tariffs on pharmaceutical imports.Aurobindo Pharma Shares Surge After Tariff Exemption - 03 Apr, 2025
Aurobindo Pharma's stock jumped 7.36% on April 3, 2025, following the U.S. administration's exemption of pharmaceuticals from reciprocal tariffs, benefiting the company's significant U.S. revenue exposure.Aurobindo Pharma Faces Potential Tariff Challenges - 02 Apr, 2025
Aurobindo Pharma may experience margin pressure due to potential tariffs of up to 35% on exports, affecting its substantial revenue from the US market.Curateq Biologics Issues CCPS to Dr. Makkapati - 21 Mar, 2025
Curateq Biologics, a subsidiary of Aurobindo Pharma, allotted 4,125,055 Compulsory Convertible Preference Shares to Dr. Satakarni Makkapati, resulting in a 2% equity stake. This will change Curateq's status from a wholly owned subsidiary to a subsidiary of Aurobindo Pharma.Aurobindo Pharma Faces Challenges Amid Expansion Efforts - 20 Mar, 2025
Aurobindo Pharma's stock has dropped 13% in 2025 due to slow US approvals and upcoming patent expirations. The company is expanding capacity and product lines, investing $300 million in a new Pen-G facility. Despite achieving record quarterly revenue, net profit declined due to foreign exchange losses. Elara Securities maintains a buy rating with a target price of ₹1,568, indicating a potential upside.Aurobindo Pharma Receives VAI Status, Shares Rise - 19 Mar, 2025
Aurobindo Pharma's Apitoria Pharma Unit V received a Voluntary Action Indicated classification from the US FDA, boosting investor confidence and share prices. Despite a decline in net profit, revenue increased year-on-year.
Insights on Aurobindo Pharma Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTProfit Spike
Netprofit is up for the last 2 quarters, 817.38 Cr → 845.81 Cr (in ₹), with an average increase of 3.4% per quarter
- POSITIVE IMPACT
Price Rise
In the last 7 days, AUROPHARMA stock has moved up by 4.7%
- POSITIVE IMPACT
Retail Holding Up
Retail Investor have increased holdings from 6.46% to 6.69% in Dec 2024 quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 10 quarters, 5.79K Cr → 8.13K Cr (in ₹), with an average increase of 3.7% per quarter
NO EFFECTAgainst Peers
In the last 1 year, Divis Laboratories Ltd has given 55.1% return, outperforming this stock by 53.4%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 51.82% of holdings in Dec 2024 quarter
- NO EFFECT
Against Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 125.9% return, outperforming this stock by 57.6%
NEGATIVE IMPACTFII Holding Down
Foreign Institutions have decreased holdings from 16.59% to 16.29% in Dec 2024 quarter
- NEGATIVE IMPACT
MF Holding Down
Mutual Funds have decreased holdings from 18.53% to 17.81% in Dec 2024 quarter
Aurobindo Pharma News
Pharma Q4 Preview: Key Earnings Expectations for Major Companies
Overall estimated growth YoY basis: Revenue +8 to 10 percent | EBITDA +9 to 12 percent | PAT +1 to 2.7 percent. Aurobindo Pharma enters Q4FY25 with a more balanced outlook, as its long-troubled injectable business begins to show signs of recovery.17 Apr, 2025 10:41 AMAurobindo Pharma Receives USFDA Approval for Rivaroxaban Tablets
Aurobindo Pharma Limited announced that it has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Rivaroxaban Tablets USP, 2.5 mg, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), XARELTO®?, 2.5 mg of Janssen Pharmaceuticals Inc. The product will be launched in first quarter of fiscal year 26. The approved product, Rivaroxaban tablets USP, 2.5mg, has an estimated US market size of USD 447 million for the twelve months ending February 2025, according to IQVIA. Aurobindo Pharma now has a total of 540 ANDA approvals (521 Final approvals and 19 tentative approvals) from USFDA. Rivaroxaban Tablet USP is used (i) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (ii) for the treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and for the reduction in the risk of recurrence of DVT and of PE (iii) for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery. Aurobindo Pharma also received tentative approval from USFDA for 10 mg, 15 mg, and 20 mg strengths of Rivaroxaban Tablets UP. The estimated market size of all the strengths of Rivaroxaban tablets US P, in the US, is USD 8.5 billion for the twelve months ending February 2020, according to IQVIA.16 Apr, 2025 06:24 PMPharma Stocks Unfazed by US Investigation into Imported Drugs
Aurobindo Pharma Ltd in fact rose 0.40 per cent to Rs 1,139.65. It is the largest Indian generic company with US sales of $1.6 billion in Calendar 2024. Aurobindo Pharma has three manufacturing sites in the US, but the production and contribution from the sites are limited.16 Apr, 2025 09:55 AMAurobindo Pharma Financials
Aurobindo Pharma Index Inclusions
Aurobindo Pharma Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 51.82% | 0.00 | |
| Foreign Institutions | 16.29% | ||
| Mutual Funds | 17.81% | ||
| Retail Investors | 6.69% | 3.51 | |
| Others | 7.4% | 11.99 |
Aurobindo Pharma Key Indicators
Aurobindo Pharma Valuation
Aurobindo Pharma in the last 5 years
Lowest (6.73x)
March 23, 2020
Today (18.97x)
April 16, 2025
Industry (53.06x)
April 16, 2025
Highest (27.59x)
December 21, 2023
Aurobindo Pharma Earnings and Dividends
Aurobindo Pharma Ltd Earnings Results
Aurobindo Pharma Ltd’s net profit fell -9.66% since last year same period to ₹845.81Cr in the Q3 2024-2025. On a quarterly growth basis, Aurobindo Pharma Ltd has generated 3.48% jump in its net profits since last 3-months.
Read More about Earnings ResultsAurobindo Pharma Ltd Dividends February,2024
In the quarter ending December 2023, Aurobindo Pharma Ltd has declared dividend of ₹1.50 - translating a dividend yield of 0.40%.
Read More about Dividends
Aurobindo Pharma Technicals Summary
Bearish
Neutral
Bullish
Aurobindo Pharma Ltd is currently in a Bullish trading position according to technical analysis indicators.
Aurobindo Pharma Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹66,410.28 Cr | 21.77% | 0.56 | ₹3,168 Cr | ₹29,001 Cr | |
| BUY | ₹14,294.72 Cr | -4.35% | 0.52 | ₹602 Cr | ₹2,851 Cr | |
| HOLD | ₹82,722.50 Cr | 29.26% | 0.64 | ₹3,854 Cr | ₹19,547 Cr | |
| BUY | ₹65,258.75 Cr | 16.3% | 0.53 | NA | NA | |
| BUY | ₹49,583.45 Cr | 20.22% | 0.56 | ₹589 Cr | ₹3,453 Cr |
About Aurobindo Pharma
The company is well known for its top products such as antibiotics, anti-malarials, cardiovascular, and anti-diabetic drugs. Its popular brands include Aurolife, Aurocare, Aurochem, and Aurovit. Aurobindo Pharma is one of the largest manufacturers of generic drugs in India, with a presence in over 150 countries worldwide.
Revenue: ₹7,893.15Cr as on December 2024 (Q4 24)
Net Profit: ₹845.57Cr as on December 2024 (Q4 24)
Listing date: 19 Oct, 1995
Chairperson Name: K Ragunathan
| Organisation | Aurobindo Pharma |
| Headquarters | Hyderabad |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
FAQs on Aurobindo Pharma Ltd
What is Aurobindo Pharma Ltd price today?
Aurobindo Pharma Ltd share price today stands at ₹1165.8, Open: ₹1165.4, Previous Close: ₹1133.4, High: ₹1165.9, Low: ₹1131.4, 52 Week High: ₹1592, 52 Week Low: ₹1010.
How to Buy Aurobindo Pharma Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Aurobindo Pharma Ltd shares
What are today's traded volumes of Aurobindo Pharma Ltd?
Today's traded volume of Aurobindo Pharma Ltd(AUROPHARMA) is 4.54L.
What is today's market capitalisation of Aurobindo Pharma Ltd?
Today's market capitalisation of Aurobindo Pharma Ltd(AUROPHARMA) is ₹66410.28Cr.
What is the 52 Week High and Low Range of Aurobindo Pharma Ltd?
How much percentage Aurobindo Pharma Ltd is down from its 52 Week High?
Aurobindo Pharma Ltd (AUROPHARMA) share price is ₹1165.8. It is down -26.77% from its 52 Week High price of ₹1592
How much percentage Aurobindo Pharma Ltd is up from its 52 Week low?
Aurobindo Pharma Ltd (AUROPHARMA) share price is ₹1165.8. It is up 15.43% from its 52 Week Low price of ₹1010